XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restatement of Previously Issued Financial Statements - Consolidated Cash Flow Statement (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net income (loss) $ (1,136) $ 2,687
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization 1,678 753
Share based compensation 1,760 1,536
Deferred income taxes (627) (776)
Bad debt expense 19 45
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:    
Accounts receivable (46) 86
Inventories - finished goods (10,185) 9,880
Prepaid income taxes 335 681
Prepaid expenses and other current assets (2,390) 451
Operating lease right-of-use assets, net 196 0
Accounts payable 9,115 (10,469)
Sales tax payable 500 498
Accrued expenses and other current liabilities 1,295 169
Lease liabilities (205) 0
Deferred memberships fees received 253 0
Income taxes payable 0 839
Net cash provided by operating activities 562 6,380
Cash flows from investing activities:    
Purchase of minority interest investment in Vetster 0 (5,000)
Acquisition of PetCareRx, net of cash acquired (35,859) 0
Purchases of property and equipment (1,153) (982)
Net cash used in investing activities (37,012) (5,982)
Cash flows from financing activities:    
Dividends paid (6,102) (6,064)
Net cash used in financing activities (6,102) (6,064)
Net decrease in cash and cash equivalents (42,552) (5,666)
Cash and cash equivalents, at beginning of year 104,086 111,080
Cash and cash equivalents, at end of year 61,534 105,414
Supplemental disclosure of cash flow information:    
Dividends payable in accrued expenses 1,507 791
As Previously Reported    
Cash flows from operating activities:    
Net income (loss) (887) 2,775
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization 1,678 753
Share based compensation 1,760 1,536
Deferred income taxes (450) (294)
Bad debt expense 19 45
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:    
Accounts receivable (46) 86
Inventories - finished goods (10,185) 9,880
Prepaid income taxes 335 681
Prepaid expenses and other current assets (2,390) 451
Operating lease right-of-use assets, net 196 0
Accounts payable 9,115 (10,469)
Sales tax payable 0 0
Accrued expenses and other current liabilities 1,369 97
Lease liabilities (205) 0
Deferred memberships fees received 253 0
Income taxes payable 0 839
Net cash provided by operating activities 562 6,380
Cash flows from investing activities:    
Purchase of minority interest investment in Vetster 0 (5,000)
Acquisition of PetCareRx, net of cash acquired (35,859) 0
Purchases of property and equipment (1,153) (982)
Net cash used in investing activities (37,012) (5,982)
Cash flows from financing activities:    
Dividends paid (6,102) (6,064)
Net cash used in financing activities (6,102) (6,064)
Net decrease in cash and cash equivalents (42,552) (5,666)
Cash and cash equivalents, at beginning of year 104,086 111,080
Cash and cash equivalents, at end of year 61,534 105,414
Supplemental disclosure of cash flow information:    
Dividends payable in accrued expenses 1,507 791
Restatement Adjustments    
Cash flows from operating activities:    
Net income (loss) (249) (88)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization 0 0
Share based compensation 0 0
Deferred income taxes (177) (482)
Bad debt expense 0 0
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:    
Accounts receivable 0 0
Inventories - finished goods 0 0
Prepaid income taxes 0 0
Prepaid expenses and other current assets 0 0
Operating lease right-of-use assets, net 0 0
Accounts payable 0 0
Sales tax payable 500 498
Accrued expenses and other current liabilities (74) 72
Lease liabilities 0 0
Deferred memberships fees received 0 0
Income taxes payable 0 0
Net cash provided by operating activities 0 0
Cash flows from investing activities:    
Purchase of minority interest investment in Vetster 0 0
Acquisition of PetCareRx, net of cash acquired 0 0
Purchases of property and equipment 0 0
Net cash used in investing activities 0 0
Cash flows from financing activities:    
Dividends paid 0 0
Net cash used in financing activities 0 0
Net decrease in cash and cash equivalents 0 0
Cash and cash equivalents, at beginning of year 0 0
Cash and cash equivalents, at end of year 0 0
Supplemental disclosure of cash flow information:    
Dividends payable in accrued expenses $ 0 $ 0